Following the prohibition of Illumina’s acquisition of GRAIL (see EUROPE B13015A1), on Thursday 12 October the European Commission adopted measures to restore the pre-merger situation and require Illumina to unwind its acquisition of GRAIL.
The Commission prohibited Illumina's acquisition of GRAIL on 6 September 2022, fearing that the merger would reduce choice in the emerging market for blood tests to detect cancers at an early stage.
Illumina and GRAIL had seriously breached European...